Quantcast
Channel: Endpoints News
Viewing all articles
Browse latest Browse all 4091

Corcept misses primary endpoint in supportive Cushing's syndrome study

$
0
0
Corcept Therapeutics announced Wednesday that its experimental treatment for Cushing’s syndrome missed the primary endpoint in a Phase 3 trial intended to support its FDA submission. While patients with hypertension who received relacorilant in the ...

Viewing all articles
Browse latest Browse all 4091

Latest Images

Trending Articles



Latest Images